Evidence map›Paper›PMID 41243223›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Injectable and In Situ Hydration-Reinforced Hybrid Bone Cements for Accelerated Bone Regeneration.

Xing Chen, Yifan Ma, Lingfei Zhao, Lingbin Che, Dianwen Song, Zihan Wu, Changsheng Liu, Yuan Yuan

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xing ChenKey Laboratory for Ultrafine Materials of Ministry of Education, School of Materials Science and Engineering, East China University of Science and Technology, Shanghai, 200237, P. R. China.
Yifan MaDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.ORCID https://orcid.org/0000-0002-9371-4365
Lingfei ZhaoKey Laboratory for Ultrafine Materials of Ministry of Education, School of Materials Science and Engineering, East China University of Science and Technology, Shanghai, 200237, P. R. China.
Lingbin CheDepartment of Orthopedics, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200080, P. R. China.
Dianwen SongDepartment of Orthopedics, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200080, P. R. China.
Zihan WuShanghai Rebone Biomaterials Co., Ltd, Shanghai, 201707, P. R. China.
Changsheng LiuKey Laboratory for Ultrafine Materials of Ministry of Education, School of Materials Science and Engineering, East China University of Science and Technology, Shanghai, 200237, P. R. China.
Yuan YuanKey Laboratory for Ultrafine Materials of Ministry of Education, School of Materials Science and Engineering, East China University of Science and Technology, Shanghai, 200237, P. R. China.ORCID https://orcid.org/0000-0001-7877-3175

Funding

Chinese Academy of Sciences-WEGO Research and Development Program 【2023】005Frontiers Science Center for Materiobiology and Dynamic Chemistry JKVD1211002National Key Research and Development Program of China 2022YFB3804300National Natural Science Foundation of China 32271401National Natural Science Foundation of China U24A20376Program of Shanghai Academic/Technology Research Leader 22XD1433900
6 · The paper itself

Abstract

Injectable bone cements are recognized as ideal solution for bone augmentation due to their minimally invasive introduction strategy. However, current clinical formulations and composites, while demonstrating improvements in certain areas, often fail to comprehensively address challenges, including rheological injectability, mechanical stability, interconnected porosity, degradability, and bioactivity. To overcome limitations, a novel bone cement comprising linear polyhydroxy PEGylated poly(glycerol sebacate) (L-PEGS) and calcium phosphate cement (CPC) is developed. The incorporation of L-PEGS enhances injectability and reinforces the mechanical weakness of CPC, resulting in improvement in compressive strength (increased by 16.7 folds) and fatigue resistance (1000 cycles). Owing to linear polyhydroxy backbone, L-PEGS initiates self-reinforcing cross-linking reaction synchronized with the hydration of CPC into hydroxyapatite. This hydration reinforcement is mediated by its abundant hydroxyl groups and high water absorption capacity, which accelerate hydration kinetics. Concurrently, the cross-linking reaction generates in situ carbon dioxide, resulting in porous microarchitecture that facilitates hydration process, enhances cement degradability, and promotes nutrient exchange and new bone ingrowth. In vitro and vivo studies confirmed that L-PEGS/CPC substantially enhances osteogenesis compared to clinical materials. Collectively, this injectable, hydration-driven, and self-reinforcing bone cement offers comprehensive solution to the challenges in current bone graft materials, holding promise for clinical bone repair.

Indexed as

Bone CementsBone RegenerationAnimalsCalcium PhosphatesCompressive StrengthDecanoatesGlycerolInjectionsMicePolymersPorosityBone Cementscalcium phosphateCalcium PhosphatesDecanoatesGlycerolpoly(glycerol-sebacate)Polymersbone regenerationhydration reinforcementinjectable hybrid bone cementin situ pore formationlinear polyhydroxy PEGylated poly(glycerol sebacate) (L‐PEGS)

Identifiers

PMID41243223
PMCPMC12866785

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.